Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy
Author: Mwasakifwa, G.
Moore, C.
Carey, D.
Amin, J.
Penteado, P.
Losso, M.
Lim, P.
Mohapi, L.
Molina, J.
Gazzard, B.
Cooper, D.
Boyd, M.
Citation: AIDS, 2018; 32(3):357-361
Publisher: Lippincott, Williams & Wilkins
Issue Date: 2018
ISSN: 0269-9370
Statement of
Gwamaka E. Mwasakifwa, Cecilia Moore, Dianne Carey, Janaki Amin, Paul Penteado, Marcelo Losso, Poh-Lian Lim, Lerato Mohapi, Jean-Michel Molina, Brian Gazzard, David A. Cooper, Mark Boyd, for the SECOND-LINE Study Group
Abstract: BACKGROUND:Resource constraints in low and middle-income countries necessitate practical approaches to optimizing antiretroviral therapy outcomes. We hypothesised that an untimed plasma lopinavir concentration (UPLC) at week 12 would predict loss of virological response in those taking lopinavir as part of a second-line antiretroviral regimen. METHODS:We measured plasma lopinavir concentration at week 12 on stored samples from the SECOND-LINE study. We characterized UPLC as: detectable and optimal (≥1000 μg/l); detectable but suboptimal (≥25 to < 1000 μg/l); and undetectable (<25 μg/l). We used Cox regression to explore the relationship between UPLC and loss of virological response over 48 weeks and backwards stepwise logistic regression to explore the relationship between UPLC and other predictors of virological failure at week 48. RESULTS:At week 48, we observed virological failure in 15/32 (47%) and 53/485 (11%) of patients with undetectable and detectable UPLC, respectively, P < 0.001. Both suboptimal [adjusted hazard ratio (HR) 2.94; 95% confidence interval (CI) 1.54-5.62; P = 0.001], and undetectable (adjusted HR 3.55; 95% CI 1.89-6.64; P < 0.001) UPLC were associated with higher rates of loss of virological response over 48 weeks. In multivariate analysis, an independent association with virological failure at week 48 and undetectable UPLC was observed after adjustment (odds ratio 5.48; 95% CI 2.23-13.42; P < 0.01). CONCLUSION:In low and middle-income countries implementing a public health approach to antiretroviral therapy treatment, an untimed plasma drug concentration may provide a practical method for early identification of patients with inadequate medication adherence and facilitate timely corrective interventions to prevent virological failure.
Keywords: antiretroviral adherence; antiretroviral therapy; HIV; low and middle-income countries; resistance; second line; untimed drug concentration; virological failure
Rights: Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
DOI: 10.1097/QAD.0000000000001688
Appears in Collections:Aurora harvest 3
Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_123900.pdfAccepted version312.29 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.